Dublin, June 21, 2022 (GLOBE NEWSWIRE) -- The "Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. The ...

Please provide your email address to receive an email when new articles are posted on . “[These findings] help clinicians be more supportive of a female with CF becoming pregnant,” Raksha Jain, MD, ...

Sionna Therapeutics, Inc. has announced the presentation of promising preclinical data at the 48th European Cystic Fibrosis Conference in Milan, showing that its nucleotide-binding domain 1 (NBD1) ...

(MENAFN- Market Press Release) July 4, 2025 7:42 am - The small molecule CFTR modulators market targets cystic fibrosis treatment, driven by innovative therapies, rising prevalence, and regulatory ...

- ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene ...

Newark, New Castle, USA, June 06, 2023 (GLOBE NEWSWIRE) -- The market analysis of the global CFTR correctors/modulators market was conducted by Growth Plus Reports in 2022 and is valued at US$ 8.93 ...

Sionna Therapeutics, Inc. announced that preclinical data on its novel cystic fibrosis (CF) treatment candidates, SION-451 and SION-719, will be presented at the European Cystic Fibrosis Society’s ...

Please provide your email address to receive an email when new articles are posted on . Triple therapy improved lung function, BMI and other factors. Patients naïve to cystic fibrosis transmembrane ...

Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference ...